+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Primary and secondary prevention of cardiovascular disease in diabetes with aspirin



Primary and secondary prevention of cardiovascular disease in diabetes with aspirin



Diabetes and Vascular Disease Research 9(4): 243-244



Diabetes is associated with an increased cardiovascular risk. The role for aspirin in diabetes is of high clinical interest. Guidelines recommend that primary prevention of cardiovascular disease (CVD) in diabetes with aspirin should be based on the individual risk for CVD. New mechanistic studies suggest that enhanced platelet turnover may partly contribute to the fact the primary prevention studies found unequivocal results in diabetes. There is initial evidence that a potential future modification of dosages in diabetes may counteract the enhancement in platelet turnover in diabetes. The use of aspirin in diabetic patients for secondary prevention of CVD is supported by key evidence. The aim of the review is to present recent studies on aspirin for prevention of CVD in diabetes and to highlight its role also in view of new mechanistic and clinical studies with aspirin. Novel aspects of aspirin, e.g. its potential role for the prevention of cancer, are also presented.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055174058

Download citation: RISBibTeXText

PMID: 22942227

DOI: 10.1177/1479164112455534


Related references

The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review. Clinical Pharmacology and Therapeutics 100(5): 500-512, 2016

Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review. Systematic Reviews 4: 88, 2016

Aspirin for Primary and Secondary Prevention of Cardiovascular Disease. Texas Heart Institute Journal 43(4): 318-319, 2017

Aspirin for primary prevention of cardiovascular disease in diabetes. Journal of Diabetes Investigation 2019, 2019

Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 80(4): 749-756, 1989

Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes?. Medical Journal of Australia 190(11): 614-615, 2009

Prevalence and population characteristics of aspirin use in the primary and secondary prevention of cardiovascular disease. American Journal of Epidemiology 141(11 SUPPL ): S71, 1995

Underutilization of aspirin in hemodialysis patients for primary and secondary prevention of cardiovascular disease. Clinical Nephrology 64(5): 371-377, 2005

Underuse of aspirin for primary and secondary prevention of cardiovascular disease events in women. Journal of Women's Health 21(4): 379-387, 2012

Preventing cardiovascular disease in patients with diabetes: use of aspirin for primary prevention. Current Cardiology Reports 17(3): 566, 2015

Aspirin for primary prevention of cardiovascular disease events in diabetes: the balancing act?. Journal of the Royal College of Physicians of Edinburgh 48(4): 332-333, 2018

Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus. Diabetes, Obesity and Metabolism 11(11): 997-1000, 2011

Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. Plos Medicine 2(12): E353, 2005

Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011-2012. Journal of the American Heart Association 3(4), 2015

Investigation of the effects of low dose aspirin therapy on primary and secondary prevention of cardiovascular disease. Nihon Rinsho. Japanese Journal of Clinical Medicine 68(5): 882-886, 2010